[{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"ee309a82-4f0b-426f-a0b1-deeeabf2fd59","acronym":"","url":"https://clinicaltrials.gov/study/NCT04802161","created_at":"2021-03-17T15:57:34.517Z","updated_at":"2025-02-25T16:32:23.537Z","phase":"Phase 2","brief_title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","source_id_and_acronym":"NCT04802161","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2","pipe":" | ","alterations":" Chr del(11q)","tags":["RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide • thalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"1ff726df-4ae8-4795-97b5-a7e91fde5bce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05208307","created_at":"2022-01-26T12:53:35.060Z","updated_at":"2025-02-25T13:12:53.198Z","phase":"Phase 2","brief_title":"Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma","source_id_and_acronym":"NCT05208307","lead_sponsor":"Emory University","biomarkers":" CD4","pipe":" | ","alterations":" Chr t(4;14) • Chr t(14;16)","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • Blenrep (belantamab mafodotin-blmf) • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2026","study_completion_date":" 10/21/2026","last_update_posted":"2024-08-12"},{"id":"7a2918a3-5cca-4af4-9ede-643ba7496c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01745588","created_at":"2021-01-18T07:39:01.782Z","updated_at":"2025-02-25T14:33:53.694Z","phase":"Phase 2","brief_title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01745588","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-03"},{"id":"7258fe47-fdbb-4505-b15b-20957550273b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04303117","created_at":"2021-01-18T20:52:07.511Z","updated_at":"2024-07-02T16:34:26.828Z","phase":"Phase 1/2","brief_title":"NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma","source_id_and_acronym":"NCT04303117","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-12"},{"id":"9dcb826a-6f40-4c36-9dae-a741f622b8ee","acronym":"DREAMM-3","url":"https://clinicaltrials.gov/study/NCT04162210","created_at":"2021-01-18T20:17:55.897Z","updated_at":"2024-07-02T16:34:36.734Z","phase":"Phase 3","brief_title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","source_id_and_acronym":"NCT04162210 - DREAMM-3","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 04/02/2020","start_date":" 04/02/2020","primary_txt":" Primary completion: 09/12/2022","primary_completion_date":" 09/12/2022","study_txt":" Completion: 06/26/2025","study_completion_date":" 06/26/2025","last_update_posted":"2024-06-10"},{"id":"d24f8d9a-9e2f-4861-9181-2b0a6f6b5ba4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05556798","created_at":"2022-09-27T14:04:44.698Z","updated_at":"2024-07-02T16:35:05.385Z","phase":"Phase 1","brief_title":"A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment","source_id_and_acronym":"NCT05556798","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-07"},{"id":"8deded4a-9926-4f1a-a26a-90e378ae94dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577755","created_at":"2023-11-14T19:14:53.297Z","updated_at":"2024-07-02T16:35:08.364Z","phase":"Phase 2","brief_title":"Pomalidomide Treatment in Patients With Kaposi Sarcoma","source_id_and_acronym":"NCT04577755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/18/2022","start_date":" 03/18/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-22"},{"id":"6c9623a6-4573-485b-b022-26e539880a69","acronym":"A061202","url":"https://clinicaltrials.gov/study/NCT02004275","created_at":"2021-01-18T09:09:12.624Z","updated_at":"2025-02-25T14:34:26.703Z","phase":"Phase 1/2","brief_title":"Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02004275 - A061202","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CYP1A2","pipe":" | ","alterations":" Chr t(14;16) • Chr del(1p)","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(14;16) • Chr del(1p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Ninlaro (ixazomib) • dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2023-12-01"},{"id":"6a45c024-4c0a-472b-844c-1cfb591a4381","acronym":"CheckMate 039","url":"https://clinicaltrials.gov/study/NCT01592370","created_at":"2022-02-17T15:52:52.744Z","updated_at":"2024-07-02T16:35:37.075Z","phase":"Phase 1/2","brief_title":"An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma","source_id_and_acronym":"NCT01592370 - CheckMate 039","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Darzalex (daratumumab) • dexamethasone • pomalidomide • lirilumab (BMS-986015)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 08/02/2012","start_date":" 08/02/2012","primary_txt":" Primary completion: 09/25/2020","primary_completion_date":" 09/25/2020","study_txt":" Completion: 12/22/2023","study_completion_date":" 12/22/2023","last_update_posted":"2023-09-13"},{"id":"5766f363-23d7-4ddf-aa99-822a48d173b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02185820","created_at":"2021-02-04T20:52:56.667Z","updated_at":"2024-07-02T16:35:44.252Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)","source_id_and_acronym":"NCT02185820","lead_sponsor":"European Myeloma Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone • pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-06-30"},{"id":"5549ff6d-d0c0-4524-812c-e784acd2dec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04305444","created_at":"2021-01-18T20:52:47.509Z","updated_at":"2024-07-02T16:35:49.171Z","phase":"Phase 2","brief_title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT04305444","lead_sponsor":"Zhejiang DTRM Biopharma","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • DTRM-555 • DTRMWXHS-12"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-05-02"},{"id":"790c7b3c-3603-4602-88a2-0f7f1e2a94af","acronym":"","url":"https://clinicaltrials.gov/study/NCT05028348","created_at":"2023-02-22T17:01:25.614Z","updated_at":"2024-07-02T16:35:54.933Z","phase":"Phase 3","brief_title":"A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma","source_id_and_acronym":"NCT05028348","lead_sponsor":"European Myeloma Network","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • dexamethasone • pomalidomide • Empliciti (elotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 222","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2023-02-22"},{"id":"609b62e0-5459-4e6f-b8b3-1e6b3e397774","acronym":"","url":"https://clinicaltrials.gov/study/NCT01495598","created_at":"2022-11-05T15:11:43.110Z","updated_at":"2024-07-02T16:36:01.485Z","phase":"Phase 1/2","brief_title":"Pomalidomide for Kaposi Sarcoma in People With or Without HIV","source_id_and_acronym":"NCT01495598","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 01/10/2012","start_date":" 01/10/2012","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 05/17/2022","study_completion_date":" 05/17/2022","last_update_posted":"2022-11-01"},{"id":"af618ed1-f3a8-4f1c-b68f-d34b62bb09f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05581875","created_at":"2022-10-17T14:56:46.978Z","updated_at":"2025-02-25T13:13:10.924Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory","source_id_and_acronym":"NCT05581875","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/20/2022","start_date":" 10/20/2022","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2022-10-17"},{"id":"2fb657ac-eed2-45a0-bd11-acbeb884bff1","acronym":"SPACE","url":"https://clinicaltrials.gov/study/NCT03113942","created_at":"2021-01-29T07:14:31.583Z","updated_at":"2024-07-02T16:36:14.293Z","phase":"Phase 2","brief_title":"Study of Pomalidomide in Anal Cancer Precursors","source_id_and_acronym":"NCT03113942 - SPACE","lead_sponsor":"Kirby Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/14/2017","start_date":" 06/14/2017","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-03-31"},{"id":"749fedcd-f229-430a-85bb-edecfae0c460","acronym":"","url":"https://clinicaltrials.gov/study/NCT04137523","created_at":"2021-01-18T20:12:24.654Z","updated_at":"2024-07-02T16:36:26.170Z","phase":"","brief_title":"Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression","source_id_and_acronym":"NCT04137523","lead_sponsor":"University of Turin, Italy","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • pomalidomide • melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/12/2019","start_date":" 08/12/2019","primary_txt":" Primary completion: 08/12/2019","primary_completion_date":" 08/12/2019","study_txt":" Completion: 09/15/2022","study_completion_date":" 09/15/2022","last_update_posted":"2021-08-18"}]